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AbstrAct
Reactive oxygen species (ROS) are implicated in tumor transformation. The 
antioxidant system (AOS) protects cells from ROS damage. However, it is also 
hijacked by cancers cells to proliferate within the tumor. Thus, identifying proteins 
altered by redox imbalance in cancer cells is an attractive prognostic and therapeutic 
tool. Gene expression microarrays in A375 melanoma cells with different ROS levels 
after overexpressing catalase were performed. Dissimilar phenotypes by differential 
compensation to hydrogen peroxide scavenging were generated. The melanotic 
A375-A7 (A7) upregulated TYRP1, CNTN1 and UCHL1 promoting melanogenesis. The 
metastatic A375-G10 (G10) downregulated MTSS1 and TIAM1, proteins absent in 
metastasis. Moreover, differential coexpression of AOS genes (EPHX2, GSTM3, MGST1, 
MSRA, TXNRD3, MGST3 and GSR) was found in A7 and G10. Their increase in A7 
improved its AOS ability and therefore, oxidative stress response, resembling less 
aggressive tumor cells. Meanwhile, their decrease in G10 revealed a disruption in the 
AOS and therefore, enhanced its metastatic capacity.
These gene signatures, not only bring new insights into the physiopathology of 
melanoma, but also could be relevant in clinical prognostic to classify between non 
aggressive and metastatic melanomas.
IntroductIon
Reactive oxygen species (ROS) has been widely 
implicated in tumor transformation. Indeed, ROS and 
antioxidants were proposed as potential therapeutic 
tools. However, changes in the redox balance may have 
different impact on tumor cells. Therefore, it is important 
to study how ROS status and the antioxidant system 
(AOS) of tumor cells affect the global response of gene 
expression. 
It has been well established that most cancer cells, 
including melanoma, are characterized by high ROS 
levels that induce mandatory steps of cancer initiation 
and progression [1–9]. Disruption of the normal redox 
balance by deregulation in AOS proteins, such as 
superoxide dismutase (SOD), catalase and glutathione and 
thioredoxin system proteins, was associated with cancer 
development [10–13]. Dysfunction of ROS-producing 
systems coevolves with the AOS to a new redox balance 
leading to the progression from melanocytes to melanoma 
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[14]. Besides, the prooxidant state in melanoma may 
also induce alterations in proteins involved either in 
melanogenesis or metastasis.
The oxidative stress exerts strong adaptive pressure 
on cancer cells, which in order to survive, promote 
the expression of ROS pathways reprogramming the 
transcriptome, proteome and metabolism [15]. The 
reversion of malignant phenotype by overexpression of 
antioxidant enzymes, such as catalase has been studied 
[16–19]. However, it is still not clear which groups of 
genes are overexpressed or down regulated in melanoma 
cells under this condition.
Besides, melanoma prognosis is still based mainly 
on histopathological criteria [20]. Thus, to enable earlier 
diagnosis and prognosis, it would be relevant to define 
new molecular markers. In this sense, coexpressed 
genes associated with the AOS response as predictors of 
melanoma development and its progression have not been 
proposed yet. 
Thus, to identify genes involved in melanoma 
progression or regression after an AOS response, we 
developed a human melanoma model with different levels 
of ROS by stably overexpressing catalase in A375 cells 
(in press, 2016). Whole genome gene expression patterns 
were analyzed by microarrays. 
Catalase overexpression triggered dissimilar gene 
expression. Differential compensation to hydrogen 
peroxide scavenging gave rise to either, melanogenic 
A375-A7 (A7) or metastatic A375-G10 (G10) 
phenotypes. In this sense, A7 upregulated genes involved 
in differentiation such as tyrosinase related protein 1 
(TYRP1), contactin 1 (CNTN1) and ubiquitin COOH-
terminal hydrolase L1 (UCHL1) [21–24], turning this 
clone less aggressive. Meanwhile, G10 downregulated 
genes, promoting an undifferentiated and invasive 
phenotype. Particularly, this clone decreased metastasis 
suppressor 1 (MTSS1) and T-Cell lymphoma invasion 
and metastasis 1 (TIAM1) genes, whose downregulation 
enhances malignant progression [25–27]. However, the 
behavior of these proteins in melanoma has received 
little attention. Moreover, A7 upregulated coexpressed 
genes associated with hydrogen peroxide metabolism. 
Downregulation of these genes was correlated with 
malignant progression, as observed in G10. Thus, 
changing the expression of one antioxidant gene in 
A375 melanoma cells triggered different phenotypes by 
compensatory reprogramming the AOS network.
Therefore, beyond these promising result 
need further validations in other melanoma models, 
the upregulation of TYRP1, CNTN1 and UCHL1, 
the downregulation of MTSS1 and TIAM1 and the 
coexpression of the AOS genes EPHX2, GSTM3, 
MGST1, MSRA, TXNRD3, MGST3 and GSR, could be 
used to classify between non-aggressive and metastatic 
melanomas.
results
Gene expression profiles
Catalase overexpression on human amelanotic 
melanoma A375 cells gave rise to a clone with increased 
polarity related to differentiated melanoma (A7), and 
another clone (G10) with disrupted polarity associated 
with malignant progression (in press, 2016). Therefore, 
differential gene expression was evaluated by microarrays 
analysis of whole genome in this model. A375 and 
PCDNA3 cells (A375 cells transfected with the empty 
vector) were also evaluated, considering their average 
results as control. 
The analysis showed 6 downregulated genes and 
31 upregulated genes from 33297 genes in A7 vs control 
(Figure 1A) and 57 downregulated and 39 upregulated 
genes in G10 vs control (Figure 1B). Besides, G10 
showed 86 downregulated and 50 upregulated genes vs 
A7 (Figure S1). No differentially expressed genes were 
found between controls. 
Functional classification analysis
Regarding DAVID functional annotation clustering 
(Table S1 and S2), the comparison between A7 and control 
(p < 0.01) showed upregulated genes involved in cell 
and biological adhesion and basement membrane terms, 
within which CNTN1 was found. By contrast, A7 did 
not downregulated any process vs control. Meanwhile, 
G10 vs A7 (p < 0.01), downregulated genes associated 
with cell projection, axon, cell morphogenesis involved 
in differentiation and neuron differentiation, neuron 
projection morphogenesis and cell adhesion terms. 
Moreover, G10 vs control (p < 0.01) downregulated not 
only most of these same terms but also, those related to 
regulation of actin cytoskeleton and cell motion. Within 
these terms, MTSS1, UCHL1 and TIAM1 appeared 
downregulated. The genes upregulated in G10 vs control 
and A7 (p < 0.01) were associated with a vast amount 
of processes involved in the immune response. Besides, 
processes involved in cell adhesion were upregulated in 
G10 vs control (p < 0.01). Regulation of transcription and 
RNA metabolic processes were upregulated in G10 vs A7 
(p < 0.01).
Validation of microarrays by quantitative  
real-time PCR (qPCR) 
Considering the functional classification of 
differentially expressed genes in A7 and G10 vs 
control (Table S1), five genes were selected to validate 
microarrays data by qPCR. The selected genes TYRP1, 
CNTN1 and UCHL1 were upregulated in A7 vs control, 
as indicated by red arrows in Figure 1A. These genes are 
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involved in melanocyte differentiation and axon guidance 
and inversely correlated with malignant progression 
[21, 24, 28]. On the contrary, MTSS1 and TIAM1, 
described as downregulated in metastatic cells [25–27], 
were almost not expressed in G10 vs control as pointed by 
green arrows in Figure 1B.
Gene expression profiles obtained by qPCR 
coincided with those obtained by microarrays analysis 
for all genes in most of the samples evaluated, validating 
microarrays data. TYRP1, CNTN1 and UCHL1 mRNA 
expression were upregulated in A7 vs controls (p < 0.05) 
(Figure 2). On the contrary, MTSS1 and TIAM1 mRNA 
expression were downregulated in G10 vs controls 
(p < 0.05) (Figure 3). 
Therefore, results support that overexpression of 
TYRP1, CNTN1 and UCHL1 in A7 is consistent with 
its differentiated melanogenic phenotype. Meanwhile, 
MTSS1 and TIAM1 downregulation in G10 supports the 
migration and metastatic ability acquired by these cells (in 
press, 2016). 
Contrasting biological processes by differential 
coexpressed genes between A7 and G10
The analysis of coexpressed genes performed 
by GSEA (Gene Set Enrichment Analysis) [29, 30] 
(Table S3 and S4) showed upregulation of clustered 
genes related to cell adhesion molecules, peroxisome, 
apoptosis and melanogenesis in A7 vs control (p < 0.05), 
supporting the differentiated and melanotic phenotype 
of these cells. Besides, A7 downregulated cell-cell 
adhesion, regulation of angiogenesis and positive 
regulation of epithelial cell migration and proliferation 
involved in wound healing vs control (p < 0.05). 
Interestingly, processes associated with G10 metastatic 
phenotype as neural crest cell migration, blood vessel 
endothelial cell migration, intussusceptive angiogenesis 
and ameboidal cell migration were upregulated in G10 
vs A7 (p < 0.05). Cell cycle, PPAR signaling pathway 
and apoptosis were downregulated in G10 vs A7 
(p < 0.05). Endothelial cell migration, several types of 
cell-cell adhesion, drug metabolic process and regulation 
of anti-apoptosis were upregulated in G10 vs control 
(p < 0.05). Consistent with G10 less proliferation and 
its apolar morphology, cell cycle and regulation of actin 
cytoskeleton clustered genes were downregulated vs 
controls (p < 0.05).
Prognostic gene signatures associate A7 
with non-aggressive and G10 with high-risk 
metastatic melanomas
The differential phenotypes between A7 and 
G10 cells correlates with less or more aggressive 
melanomas. Their gene expression profiles were assessed 
against coexpressed genes of melanoma prognostic 
signatures associated with invasion, differentiation, 
aggressiveness and metastasis (Table 1). A7 cells, unlike 
G10, coexpressed genes associated with prognostic 
signatures of less aggressive, non-metastatic and 
more differentiated melanomas. Particularly A7, 
overexpressed TYRP1, CITED, TYR, MLANA, ATP10A 
and OCA2. These genes are involved in melanocytic 
differentiation and were described as downregulated 
in aggressive and metastatic melanomas compared to 
normal melanocytes. Meanwhile, HLA-DRA, INHBA, 
DKK1, CTGF, PMP22, FLRT3 and NRCAM genes, 
upregulated in G10, were described as overexpressed 
in invasive melanomas (Figure 4). These results suggest 
that differential responses of the AOS network induced 
by stable catalase overexpression would mediate not 
only melanocyte differentiation but also invasion and 
metastasis, supporting in vitro and in vivo results (in 
press, 2016). 
Catalase overexpression induced differential 
AOS responses between A7 and G10 
An AOS gene network was manually designed 
(Figure 5) in order to study possible compensation 
mechanisms induced by A7 and G10 cells in response 
to catalase overexpression. The AOS gene network was 
differentially expressed between A7 and G10 (Figure 6). 
Remarkably, the coexpressed genes upregulated in A7, 
GSTM3, NOX4, TXNRD3, EPHX2, MSRA, GSR, CAT, 
MGST3, MGST2 and MGST1 were downregulated in G10 
vs controls (p < 0.05). Moreover, G10 also downregulated 
GPX7, PRDX5, PRDX6, DHCR24, VIMP, ATOX1, 
GLRX2, GSTP1 and GSTO2 vs controls (p < 0.05). 
Interestingly, A7 did not downregulate any gene of this 
AOS network. Besides, only A7 upregulated GCLC and 
NFE2L1. Meanwhile, G10 upregulated GSTM1, SOD1, 
PREX1, CYGB, PRDX2, OXR1, APOE, BNIP3 and 
HMGA1 vs controls (p < 0.05).
These results indicate that A7 upregulated 
peroxidase activity, hydrogen peroxide metabolic 
processes and cellular response to hydrogen peroxide. 
Meanwhile, these processes were downregulated in 
G10. Besides, G10 unlike A7, also downregulated 
certain genes associated with response to oxidative 
stress and glutathione metabolic and glutathione 
derivative biosynthetic processes. Finally, the complex 
gene networks associated with signaling pathways and 
bibliographic prognostic signatures that were induced by 
catalase overexpression after reprogramming the AOS 
network are shown in Figure 7. 
Therefore A7, by increasing the metabolism of 
hydrogen peroxide, reduced more efficiently ROS levels, 
resembling to less aggressive tumor cells. Meanwhile 
G10, by having reduced ability to respond to oxidative 
stress, increased its ROS levels conducting to migration 
and malignant progression. 
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Figure 1: Differential gene expression and clustering analysis of upregulated and downregulated genes in A7 (A) and 
G10 (B) cells. Average result from A375 and PCDNA3 cells were used as control. Genes selected for qPCR analysis are indicated with 
colored arrows (red for upregulated in A7 vs controls and green for downregulated in G10 vs controls). Analysis was conducted with lfc = 
2 and p ≤ 0.0001. Key color: red for upregulated and green for downregulated genes. 
Oncotarget41158www.impactjournals.com/oncotarget
Table 1: Melanoma Prognostic Signature
Prognostic Signature
Number of Genes/Gene 
Group Total Number
P Value Reference
Upregulated A7 vs Control
Up regulated genes in neural crest development of 
melanocytes, differentiation and pigmentation and 
down regulated genes in angiogenesis, neurogenesis, 
immunomodulation and interaction and remodeling 
extracellular environment
39/65 0 Jeffs et al., 2009
Genes downregulated in aggressive melanoma cells 24/60 0 Ryu et al., 2007
Genes with low expression in metastatic melanomas vs 
melanocytes 8/23 0 Riker et al., 2008
Genes with low expression in primary cutaneous 
melanomas vs melanocytes 12/21 0 Riker et al., 2008
Genes downregulated in metastatic vs primary 
melanomas 6/38 0,036 Jaeger et al., 2007
Downregulated in A7 vs Control
Genes upregulated in positive metastatic melanoma 69/183 0 Winnepenninckx et al., 2006
Genes upregulated in vertical vs radial growth 
melanomas 26/48 0 Ryu et al., 2007
Genes downregulated in melanomas with low 
proliferative and high metastatic capacity 4/5 0,002 Hoek et al., 2006
Genes upregulated in melanomas with low proliferative 
and high metastatic capacity 4/5 0,004 Hoek et al., 2006
Upregulated in G10 vs Control
Prolonged survival 9/50 0 Bogunovic et al., 2009
Genes upregulated in MGP melanoma cells vs 
melanocytes 10/29 0 Pfaff Smith et al., 2005
Down regulated genes in neural crest, melanocyte 
development, differentiation and pigmentation and 
up regulated genes in angiogenesis, neurogenesis, 
immunomodulation and interaction and remodeling of 
extracellular environment
12/31 0,008 Jeffs et al.,2009
Genes upregulated in melanomas with low proliferative 
and high metastatic capacity 3/5 0,008 Hoek et al., 2006
Genes downregulated in melanomas with low 
proliferative capacity and high metastatic capacity 2/5 0,008 Hoek et al., 2006
Genes upregulated in vertical vs radial growth 
melanomas 13/48 0,012 Ryu et al.,2007
Downregulated in G10 vs Control
Genes downregulated in metastatic melanomas vs 
primary melanomas 4/17 0 Jaeger et al., 2007
Molecular signature of metastatic melanomas 3/11 0,016 Wang et al., 2012
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Figure 2: Validation of microarray data by qPCR analysis of selected A7 upregulated genes: TYRP1, CNTN1 and 
UCHL1. A375 and PCDNA3 cells were used as control cells. Four RNA samples (1–4) were evaluated per condition. The same RNA 
samples were used for both assays for comparison purposes. (A–b and G) Microarray gene expression profiles of TYRP1, CNTN1 and 
UCHL1. (c–d and H): mRNA expression profiles of selected genes determined by real time PCR relative to GAPDH. (e–F and I): Results 
of mean ± SD of qPCR analysis vs controls or G10, *p < 0.05, **p < 0.01, ***p < 0.001. 
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dIscussIon
This work demonstrated a differential response of 
the AOS network induced by catalase overexpression 
in A375 melanoma cells. Moreover, the AOS gene 
expression profiles found in A7 and G10 correspond with 
their biological changes, where more or less aggressive 
melanomas were induced (in press, 2016).
The prooxidant state in melanoma induces 
alterations in proteins involved in melanogenesis, such 
as tyrosinase and TYRP1 [31, 32]. A7 cells upregulated 
coexpressed genes involved in melanogenesis, peroxisome 
and cell adhesion and downregulated genes of epithelial 
cell migration. Particularly, A7 upregulated TYRP1, 
CNTN1 and UCHL1, which participate in melanocyte 
differentiation and axon guidance [21, 24, 28]. This 
indicates that A7 changed to a more differentiated and less 
aggressive melanoma. 
TYRP1 is involved in melanin synthesis. Thus, 
its overexpression in A7, not only at mRNA but also at 
protein level (in press, 2016), supports the melanogenesis 
induction. Besides, A7 overexpressed CNTN1, a 
cell adhesion molecule involved in nervous system 
development, particularly in oligodendrocyte maturation 
Figure 3: Validation of microarray data by qPCR analysis of selected G10 downregulated genes: MTSS1 and TIAM1. 
A375 and PCDNA3 cells were used as control cells. Four RNA samples (1–4) were evaluated per condition. The same RNA samples were 
used for both assays for comparison purposes. (A–b) Microarray gene expression profiles of MTSS1 and TIAM1. (c–d) mRNA expression 
profiles of selected genes determined by real time PCR relative to GAPDH. (e–F) Results of mean ± SD of qPCR analysis vs controls or 
A7, *p < 0.05, ***p < 0.001.
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[23] and neurite extension [33]. This could favor A7 
progression into neuronal-like morphology; as evidenced 
by its polarity (in press, 2016). Reduced UCHL1 was 
associated with worse outcome in primary melanoma. 
Besides, primary lesions present higher UCHL1 
expression than metastatic lesions [21]. Suppression of 
UCHL1 was postulated as an early step of melanoma 
development, given that melanocytes present high levels 
of UCHL1, while benign nevi lack this protein [34]. 
Moreover, high levels of MTSS1, an actin-binding protein, 
inhibited migration in fibroblasts [35] and in glioblastoma 
cells inhibited cell growth, colony formation, migration 
and invasion [36]. Introducing wild-type MTSS1 or a non-
degradable MTSS1 into breast or prostate cancer cells 
with low levels of MTSS1 inhibited cell proliferation and 
migration [37]. Thus, increased MTSS1 in A7 reinforced 
its milder malignancy. However, there still controversial 
results about MTSS1 influence in cancer progression [38]. 
Conversely, G10 upregulated coexpressed genes 
involved in cell migration and angiogenesis, while 
downregulated those involved in cell cycle and apoptosis. 
These results correspond to the ability of G10 to migrate 
Figure 4: Melanoma prognostic signatures. Co-overexpressed clustered genes defined a priori from bibliographic prognostic 
signatures by GSEA in A7 and G10 vs control (average result of A375 and PCDNA3). Query genes are represented by circles with gray 
stripes. Besides, connections among query genes linked to each other and to neighboring genes (smooth circles) are represented in the figure 
with different color lines according to their type of interaction. Gene colors represent the functions to which they are associated. Networks 
are visualized by GeneMania.
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Figure 5: Network of 111 genes associated to the antioxidant system. The AOS network was manually designed to be analyzed 
by GSEA. Connections between genes linked to each other and to neighboring genes are represented in the figure with different color lines 
according to their type of interaction. Gene colors represent the functions to which they are associated. Network visualized by Gene Mania.
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and metastasize (in press, 2016). Certainly, MTSS1 and 
TIAM1 were almost absent in G10 cells, as described 
in metastatic and poor prognosis cancers [25, 36, 37, 
39–44]. Thus, loss of MTSS1 in G10 confirms its shift 
to a more aggressive melanoma. TIAM1 is a guanine 
nucleotide exchange factor that activates Rac (Rac-GEF). 
It regulates cell shape and invasiveness in epithelial cells 
and fibroblasts. Metastatic melanoma cells overexpressing 
TIAM1 turned the mesenchymal phenotype into an 
epithelial-like phenotype, whereas its downregulation 
enhanced malignant progression [26, 27]. The almost 
absence of TIAM1 in G10 supports its increased metastatic 
ability [26, 45]. 
Therefore, not only the absence of MTSS1 and 
TIAM1 expression in G10, but also high levels of CAP1 
and cofilin-1 (in press, 2016), could be key regulators 
in promoting migration and malignant progression in 
G10. On the contrary, upregulation of TYRP1, CNTN1 
and UCHL1 in melanoma could be reversing malignant 
conditions. Thus, the expression of these genes could 
be used to classify the progression of melanoma from a 
non-aggressive and differentiated to a dedifferentiated 
and metastatic one. These promising results regarding 
its prognostic significance require further in-depth 
investigations.
Cells mount a transcriptional AOS response to 
scavenge the ROS that arise from chemical, physical, and 
metabolic challenges. This protective program has been 
shown to reduce carcinogenesis [15]. However, it is also 
hijacked by established cancers to thrive and proliferate 
within the hostile tumor microenvironment and to gain 
resistance against chemo- and radiotherapies. Thus, 
targeting the AOS response proteins of cancer cells is an 
attractive therapeutic strategy. Therefore, to understand 
which proteins of the AOS are exploited by melanoma 
in order to decrease or increase its malignancy, the AOS 
Figure 6: Coexpressed genes of the AOS network in A7 and G10. Coexpression of the AOS genes in A7 and G10 vs control 
(average result of A375 and PCDNA3). Query genes are represented by circles with gray stripes. Besides, connections among query genes 
linked to each other are represented in the figure with different color lines according to their type of interaction. Gene colors represent the 
functions to which they are associated. Network is visualized by GeneMania.
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Figure 7: Gene networks associated with signaling pathways and prognostic signatures after reprogramming the AOS 
network in A7 and G10. Coexpression of genes supports the different phenotypes of A7 and G10 vs control (average result of A375 and 
PCDNA3). Up or downregulated genes are represented by red or green circles, respectively (Network Nodes). Connections among genes 
linked to each other are represented in the figure with different color lines according to their type of interaction (Network Links Legend). 
Arrows show genes from prognostic signatures associated with aggressive melanomas. The upregulation of these genes in A7 supports its 
less aggressive phenotype while in G10, its more aggressive one. Networks are visualized by GeneMania.
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network was studied. The AOS network showed 19 
coexpressed genes downregulated in G10, while 10 of 
them were upregulated in A7. Interestingly, A7 did not 
downregulated any gene. 
Regarding those 10 genes upregulated in A7 and 
downregulated in G10, EPHX2, a cytosolic epoxide 
hydrolase, was suggested to prevent progression and 
metastasis in breast cancer [46]. MGST1 is a microsomal 
glutathione transferase 1, which also displays glutathione 
peroxidase activity. Overexpression of this enzyme 
protected MCF7 cells from oxidative damage by 
decreasing intracellular ROS levels [47, 48]. MSRA 
(methionine sulfoxide reductase A), which acts as ROS 
scavenger protecting proteins from oxidation, was found 
downregulated in metastatic hepatocellular carcinoma 
[49] and breast cancer [50]. Moreover, MSRA silencing 
in breast cancer cells increased ROS levels, resulting 
in extracellular matrix degradation and upregulation 
of VEGF, which support tumor growth in vivo [50]. 
Furthermore, skin antioxidant network includes not only 
interceptive antioxidants that dissipate ROS, but also 
specific repair enzymes such as MSRA, which reverse 
macromolecular damage. These two mechanisms work 
together to maintain a delicate redox balance, crucial 
for homeostasis. In this sense, melanocytes possess 
high levels of MSRA, MSRB and thioredoxin reductase 
[51, 52]. Particularly, murine melanoma cells increased 
the expression of TXNRD3 (thioredoxin reductase 3) 
during melanogenesis [53]. Downregulation of GSTM3 
(glutathione-S-transferase Mu 3) was associated with 
metastasis in clear-cell renal-cell carcinoma [54] and 
breast [55] and colon cancer cells [56]. A proteomic 
analysis of MCF-7 breast cancer cells expressing 
constitutively active MEK5/Erk5, showed GSTM3 
downregulation related to epithelial mesenchymal 
transition [55]. Besides, GSTM3 and also MGST3 
(Microsomal Glutathione S-Transferase 3) were induced 
in human colon adenoma cells by the chemoprotector 
butyrate, while not in highly transformed neoplastic 
colorectal cells. Moreover, butyrate induced catalase in 
the primary colon non transformed cells [56]. Inhibition of 
GSR (Glutathione Reductase) activity induced oxidative 
stress, evidenced by intracellular ROS increase and 
peroxidation of mitochondrial membrane in melanoma 
cells. Therefore, the coexpressed upregulated genes 
EPHX2, GSTM3, MGST1, MSRA, TXNRD3, MGST3 
and GSR in A7 would be increasing the ability of A7 
cells to respond to oxidative stress. This protection from 
oxidative damage would be stimulating melanogenesis. 
These changes in gene expression profile led A7 cells 
to the acquisition of differentiated features, reversing 
malignancy. On the other hand, downregulation of 
these genes in G10 may be related to its worse ability 
to respond to oxidative stress. Therefore, intracellular 
ROS increase would be triggering dedifferentiation and 
so malignant progression.
Concerning the other 9 genes downregulated in G10, 
ATOX1 (antioxidant-1) is a copper-dependent transcription 
factor that mediates copper-induced cell proliferation. 
ATOX1 inhibition reduced copper-stimulated cell 
proliferation in mouse embryonic fibroblasts and non-small 
cell lung cancer cells [57, 58]. Adrenocortical carcinoma 
was characterized by silencing of genes on chromosome 
11q13, including PRDX5 (peroxiredoxin 5) [59]. PRDX6 
presented reduced levels in papillary thyroid carcinomas 
compared to non-neoplastic tissues. A correlation between 
the presence of lymph node metastasis and low PRDX6 
levels was also described [60]. The progression from low-
grade to high-grade prostate carcinoma and metastases is 
mediated by down-regulation of the androgen receptor 
target genes, including DHCR24 (24-Dehydrocholesterol 
Reductase) [61]. Reduced mRNA and protein expression 
of GSTP1 (glutathione S-transferase-pi) was found 
in neuroblastoma cell lines and high risk NB tumor 
samples [62]. Likewise, inverse correlation between 
GSTP1 expression and Barrett’s esophageal metaplasia-
dysplasia-adenocarcinoma sequence was demonstrated 
[63]. GPX7 (glutathione peroxidase 7) may function as 
tumor suppressor. It is frequently silenced in esophageal 
adenocarcinoma (EAC). The dysfunction of GPX7 in 
esophageal cells increases ROS levels and oxidative DNA 
damage, which are common risk factors for Barrett’s 
esophagus and EAC [64, 65]. Thus, downregulation of 
ATOX1, PRDX5, PRDX6, DHCR24, GSTP1 and GPX7 
in G10 supports its worse outcome. 
Regarding the two genes that were upregulated only 
in A7, GCLC (glutamate-cysteine ligase, catalytic subunit) 
and NFE2L1 (nuclear factor erythroid-derived 2-like 1), 
high expression of GCLC, the rate-limiting enzyme 
in glutathione synthesis, was associated with lower 
intracellular ROS and cell proliferation in 36 melanoma 
cell lines and also with better 5-year overall survival in 
patients with melanoma. Besides, invasiveness and switch 
from E-cadherin to N-cadherin expression were promoted 
in melanoma cells with lower GCLC expression [66]. In 
breast cancer, GCLC expression was inversely correlated 
with malignancy [67]. NFE2L1 functions as transcription 
factor that binds to antioxidant response element (ARE) 
of DNA. Its somatic inactivation is involved in hepatic 
cancer induction. Hepatocytes lacking NFE2L1 exhibited 
increased oxidative stress and impaired expression of 
antioxidant genes [68, 69]. In human skin tumors NFE2L1 
was lower than in normal skin [70]. The involvement of 
NF2L1 has also been described in osteoblast differentiation 
[71, 72]. Thus, GCLC and NFE2L1 upregulation in A7 
may contribute to both the increased ROS scavenging 
capacity compared with G10 and controls and its more 
differentiated and less aggressive melanoma.
Therefore, as far as we are concerned, this is the 
first time that a human melanoma model allowed to 
define a group of genes from the AOS downregulated by 
melanoma cells to take advantage to spread new areas and 
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metastasize. Meanwhile, upregulation of this group of 
genes reversed malignant features.
MATeRIALS AND MeTHODS
Cell culture and transfection of catalase
Low-passages human amelanotic melanoma cell line 
A375 was kindly given by Dr. E. Medrano (Huffington 
Center on Aging, Departments of Molecular & Cellular 
Biology and Dermatology, Baylor College of Medicine, 
Houston, Texas, USA). All the experiments with these 
cells were performed with less than 5 passages from 
thawing. Cells were cultured as previously described 
[73]. Stable transfected cells were maintained in identical 
conditions with 700 µg/ml geneticin (Sigma). Cells were 
regularly tested to be mycoplasma-free.
A375-A7 and A375-G10 cells overexpressing 
catalase (in press, 2016), referred in this work as A7 
and G10 respectively, were used. Due to their intriguing 
differential responses to catalase overexpression already 
described in the mentioned paper, whole genome 
microarrays experiments were performed. A375-PCDNA3 
(transfected with empty vector, referred here as PCDNA3) 
and A375 cells were used as controls in the microarrays 
experiments. 
RNA isolation and microarray experiment
Total RNA samples were isolated from cultured cells 
using RNAspin Mini RNA Isolation Kit (GE Healthcare), 
following manufacturer instructions. RNA quantity and 
quality were determined by NanoDrop2000 photometer 
(Thermo). RNA integrity was assessed evaluating the ~2:1 
ratio of 28S:18S bands in 1% agarose gel electrophoresis 
(Figure S2). Four biological replicates were used per 
condition. 
Biotin-labeled cRNA was generated and hybridised 
to Affymetrix Human Genome Chip (GeneChip® Human 
Gene 1.0 ST) following the manufacturer’s instructions 
(Affymetrix, Santa Clara, USA) by the Agricultural Plant 
Physiology and Ecology Research Institute (IFEVA), 
University of Buenos Aires, Argentina. 
Microarray analysis and data processing
Differential gene expression among human 
amelanotic melanoma cells, A375, and the two established 
catalase-overexpressing clones with different phenotypes 
(A7, melanotic and non-invasive and G10, amelanotic 
and invasive) was evaluated by the bioinformatic analysis 
of whole genome microarrays (GeneChip® Human Gene 
1.0 ST Array, Affymetrix). A375 and PCDNA3 cells were 
used as controls.
The analysis was performed by using the R 
programming language (2.12.0) [74] and different tools 
of Bioconductor [75]. The libraries “affy”, “limma”, 
“oligo”, “affxparser”, “Iranges”, “gplots”, “Biobase”, 
“Biostrings”, “cluster”, “hugene10stprobeset.db”, “Go.
db”, “preprocess Core”, hugene10sttranscriptcluster.db”, 
“pd.hugene.1.0.st.v1”, “pd.hugene.1.1.st.v1”, “org.Hs.eg.
db”, “annotate” and KEGG.db” were used. Background 
correction and normalization of data were performed 
by Robust Multi-array Average (rma) both for probe set 
and core. Differential gene expression was evaluated by 
Limma package (Linear Models for Microarray Data). Log 
fold change (lfc) and p value parameters were established. 
In order to determine those genes to be analyzed for 
functional classification or qPCR validation a 1 and 2 lfc 
were used respectively. Both analyses were performed 
with a p < 0.001.
The differential genes obtained were functionally 
classified by DAVID (Database for Annotation, 
Visualization and Integrated Discovery) [76, 77]. DAVID 
Functional Annotation Clustering tool was performed by 
using the annotation terms: Disease (OMIM_disease), 
Gene Ontology (GOTERM_BP_FAT, GOTERM_CC_FAT, 
GOTERM_MF_FAT), Pathways (BBID, BIOCARTA, 
KEGG_PATHWAY, REACTOME_PATHWAY) and Tissue 
Expression (UP_TISSUE). The classification stringency was 
selected as medium and the options were selected as default.
Significant and concordant differences between 
phenotypes were evaluated by GSEA (Gene Set 
Enrichment Analysis) [29] with a priori defined gene sets 
collected from Gene Ontology Database [78] (131 gene 
groups) and KEGG (Kyoto Encyclopedia of Genes and 
Genomes) [79–81] (19 gene groups). These selected gene 
sets are associated with cell proliferation, melanoma, 
cell cycle, melanogenesis, apoptosis, cell adhesion, 
vascularization, angiogenesis, peroxisome, cell migration, 
regulation of actin cytoskeleton, autophagy regulation, 
oxidative stress, invasion, cell motility, DNA damage 
response, drug exportation, drug metabolism, immune 
response and inflammation (Table S5). An additional set 
of 111 genes related to the antioxidant system [82–85] was 
manually defined, visualized by GeneMANIA database 
[86] and studied under the same criteria (Figure 5 and 
Table S6). This type of analysis was also performed with 
39 bibliographic predictive gene signatures of melanomas, 
associated with invasion, differentiation, aggressiveness 
and metastasis [87–98] (Table S7). Coexpressed genes 
obtained by the analysis were visualized by GeneMANIA 
database [86] via GeneMANIA web or via Cytoscape 
plugin [99].
Validation of microarrays data by quantitative 
real-time PCR (qPCR)
In order to select genes differentially expressed to 
validate the microarray results by qPCR, a 2 lfc and p < 0.001 
were used. The selected genes were TYRP1, CNTN1, 
UCHL1, MTSS1 and TIAM1. Human GAPDH was used 
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as normalization control. Total RNA samples isolated for 
microarray experiments were used to validate microarray 
experiments by qPCR. The cDNA was synthesized using 
polymerase reverse transcriptase (SuperScript™ II, 
Invitrogen) following manufacturer’s indications. Four 
biological replicates were used per condition. 
To perform qPCR 15 µl final reaction volume, 
7 µl Master mix (Maxima SYBR Green qPCR Master 
Mix, Biotium 2X), 0.2 µl primers 10 µM, 3 µl of cDNA 
1:50 and free nuclease water (Biodynamics) were used. 
Sequences of primers (all from Invitrogen) and cycling 
conditions are detailed in Table 2. Quantitative real-
time PCR assays were carried out in a QIAGEN’s q 
PCR cycler. The Pfaffl mathematical model for relative 
quantification was used to calculate the mRNA expression 
level (normalized to GAPDH) [8].
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